Demand for GLP-1s couldn’t be more clear. Yet for obesity-indicated therapies, 90% of that demand never becomes treatment. Payer rejections, cost concerns, and early drop-off drown out the signal between a written prescription and a patient on therapy. This paper shows you where the static creeps in.

Download your copy to learn why:

• GLP-1 demand leaks happen and how to boost first-fills and therapy persistence
• Obesity coverage lags behind diabetes, and how including specific comorbidities when prescribing may boost claim approvals
• Sticker shock at the pharmacy sends patients home empty-handed and how to proactively address cost barriers